Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Boehringer Ingelheim
McKinsey
AstraZeneca
Baxter

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR DILANTIN-30


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Dilantin-30

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00005951 ↗ Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma Completed National Cancer Institute (NCI) Phase 1 2000-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus temozolomide in treating patients who have recurrent primary malignant glioma.
NCT00005951 ↗ Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma Completed Duke University Phase 1 2000-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus temozolomide in treating patients who have recurrent primary malignant glioma.
NCT00040469 ↗ Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies Terminated Center for Cell and Gene Therapy, Baylor College of Medicine Phase 2 2000-08-01 The major goal of this study is to determine the risks and benefits of bone marrow transplants in patients with severe thalassemia or sickle cell disease. Participation in this project will be for two years.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Dilantin-30

Condition Name

Condition Name for Dilantin-30
Intervention Trials
Leukemia 3
Traumatic Brain Injury 3
Gliosarcoma 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Dilantin-30
Intervention Trials
Seizures 5
Glioma 4
Brain Injuries, Traumatic 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Dilantin-30

Trials by Country

Trials by Country for Dilantin-30
Location Trials
United States 22
Singapore 1
Korea, Republic of 1
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Dilantin-30
Location Trials
Ohio 3
Texas 3
North Carolina 3
Pennsylvania 2
New York 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Dilantin-30

Clinical Trial Phase

Clinical Trial Phase for Dilantin-30
Clinical Trial Phase Trials
Phase 4 6
Phase 3 2
Phase 2 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Dilantin-30
Clinical Trial Phase Trials
Completed 13
Terminated 8
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Dilantin-30

Sponsor Name

Sponsor Name for Dilantin-30
Sponsor Trials
Baylor College of Medicine 3
National Cancer Institute (NCI) 3
Duke University 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Dilantin-30
Sponsor Trials
Other 35
Industry 10
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Merck
Colorcon
Medtronic
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.